Cu(II)ATSM

Drug Profile

Cu(II)ATSM

Alternative Names: copper(II)-ATSM; Copper(II)-diacetyl-di(N4-methylthiosemicarbazone); Cu-ASTM; Cu-diacetyl-bis(N4-methylthiosemicarbazonate); diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Melbourne
  • Developer Collaborative Medicinal Development; Procypra Therapeutics
  • Class Small molecules
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Amyotrophic lateral sclerosis
  • Phase I Parkinson's disease

Most Recent Events

  • 05 Jul 2017 Phase-I clinical trials in Parkinson's disease in Australia (PO) (NCT03204929)
  • 04 Jul 2017 Collaborative Medicinal Development plans a phase I trial for Parkinson's disease (NCT03204929)
  • 08 May 2017 Phase-I/II clinical trials in Amyotrophic lateral sclerosis in Australia (PO) (NCT03136809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top